Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;10(16):906.
doi: 10.21037/atm-22-3164.

Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature

Affiliations
Review

Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature

Aihua Li et al. Ann Transl Med. 2022 Aug.

Abstract

Background: Many patient-reported outcome (PRO) on disease severity quality of life (QOL) have been developed for atopic dermatitis (AD) patients. However, none of them on the reliability and validity of the instruments was sufficient for their application in clinical studies. The objective of this study is to identify and assess the quality of recently developed PROs for disease severity and QOL in English and Chinese in AD patients.

Methods: We conducted a systematic review of PROs for disease severity and QOL for AD from PubMed, Web of Science, PsycINFO and ERIC (English literatures), and CNKI and Wanfang Data (Chinese literatures) from September 2010 to December 2021 with string including "atopic dermatitis" and "scaling". All studies were screened by 2 reviewers. After being removed duplications, the studies developed the instruments for the AD patients, were reported by patients, and assessing the disease severity or QOL were included.

Results: Twenty-six instruments were retrieved. Three single-item Numeric Rating Scale (NRS) and 8 multidimensional instruments assessing disease severity and 15 assessing QOL were found to be originally developed in English (n=23) or Chinese (n=3). After full assessment on the reliability and validity, 3 NRS and 9 multidimensional instruments were recommended. The 3 NRS were Peak Pruritus/Itch NRS, Skin Pain NRS and Sleep Disturbance (SD) NRS. The multidimensional instruments for disease severity included the Patient-Oriented Eczema Measure (POEM), the patient oriented-SCORAD (PO-SCORAD), and Atopic Dermatitis Symptom Score (ADSS), and the instruments for QOLs included Infant's Dermatology Quality of Life Index (IDQOL), Children's Dermatology Life Quality Index (CDLQI), Atopic Dermatitis Control Tool (ADCT), PROMIS® Itch Questionnaire Mood and Sleep (PIQ-MS), PROMIS-Sleep Disturbance (PROMIS-SD), and PROMIS-Sleep-Related Impairment (PROMIS-SRI) for QOL. However, none of the Chinese PROs either originally developed or adapted were fully validated.

Discussion: Single-item NRS is a complement to multidimensional PROs in assessing the disease severity of AD. Quality of these instruments vary greatly and only a few instruments that meet the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) standards are recommended. Therefore, standardization of PROs is essential for developing new instruments, and for adapting a PRO in other populations with different culture and languages.

Keywords: Atopic dermatitis (AD); patient report outcome (PRO); quality of life (QOL).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3164/coif). AL, MZ, JZ, and XX are from Sanofi (China) Investment. YY and XL are from Shanghai Jusure Health Technology. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of the search procedure adapted from the 2020 PRISMA statement. Reason 1 refers to ‘Instruments were not patient reported outcomes or contain at least one domain that is self-reported’; Reason 2 refers to ‘Instrument was not developed for measurement purposes’; Reason 3 refers to ‘No psychometric validation was available for the instrument or the instrument had poor psychometric properties’; Reason 4 refers to ‘Instruments not for assessing the QOL or the disease severity or the QOL of patients with AD’. *, duplicate refers to overlapped studies across reason 1 to 4. QOL, quality of life; AD, atopic dermatitis.

References

    1. Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192-9. 10.1111/j.1525-1470.2005.22303.x - DOI - PubMed
    1. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60:984-92. 10.1111/j.1742-1241.2006.01047.x - DOI - PubMed
    1. Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol 2021;35:180-7. 10.1111/jdv.16846 - DOI - PMC - PubMed
    1. Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther (Heidelb) 2017;7:1-23. 10.1007/s13555-016-0170-1 - DOI - PMC - PubMed
    1. Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004;114:607-11. 10.1542/peds.2004-0374 - DOI - PubMed